Personalized Cancer Care Conference

Zänker, Kurt S.; Mihich, Enrico; H, Huber; Børresen-Dale, Anne Lise

doi:10.3390/jpm3020070

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this retrospective study might give a rationale to initiate a prospective study with established biomarkers for CRF and to integrate a phyto-pharmacologic remedy into postoperative chemo- or chemo-radiotherapy protocols and thereby improving individually [ 5 ] inflammatory activities and HRQoL resulting in decreasing CRF symptoms.…”

Section: Introductionmentioning

confidence: 99%

Targeting Inflammation in Cancer-Related-Fatigue: A Rationale for Mistletoe Therapy as Supportive Care in Colorectal Cancer Patients

Bock¹,

Hanisch²,

Matthes³

et al. 2014

IADT

View full text Add to dashboard Cite

Background: Cancer-related fatigue (CRF) affects a majority of patients (pts) with symptoms lasting up to several years after finishing therapy. These symptoms lead to decreased health related quality of life. Fatigue during treatment for colorectal cancer is common, but poorly understood and can affect compliance with post-surgical cancer therapy. We examined the fatigue levels during first-line chemo- or radio-chemotherapy protocols, which were supported by a pharmaceutical mistletoe preparation (Iscador®Qu) (181patients). We compared the outcome to a parallel control group (143 patients), which did not receive this supportive care treatment. Methods: The medical records of 324 patients with non-metastasized colorectal cancer (UICC stage I - III), which were obtained from hospitals and resident physicians, were assessed. The documented treatment decision by chemo- or radio-chemotherapy supported by mistletoe interventions was followed for a median treatment period of 8.6 months. During the post-surgical treatment period the patients were diagnosed twice for the presence of fatigue symptoms by structural interviews carried out by physicians. Results: At the end of the median treatment period, 16/181 patients (8.8%) were diagnosed with CRF in the supportive care group and 86/143 (60.1%) in the chemo – or radio-chemotherapy group without supportive mistletoe medication. Multivariable-adjusted ORs provided evidence for a chance to improve CRF by supportive mistletoe medication compared to chemo- or radio-chemotherapy alone over the time of treatment. The OR = 10.651 (95% CI 5.09-22.28; p < 0.001) declined from the first visit to OR = 0.054 (95 CI 0.02-0.13; p < 0.001) at the end of therapy. Furthermore, 14 confounding factors for risk assessment of CRF were compared by means of forest plots. It turned out that the hospital versus office-based treatment and the co-morbidity/inflammation represent independent but important determinants for fatigue levels. Conclusion: The clinically used mistletoe medication (Iscador®Qu) is the first candidate to be included in a supportive care modus into chemo- or chemo-radiotherapy protocols for colorectal patients to improve CRF without discernable toxicities.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting Inflammation in Cancer-Related-Fatigue: A Rationale for Mistletoe Therapy as Supportive Care in Colorectal Cancer Patients

Bock¹,

Hanisch²,

Matthes³

et al. 2014

IADT

View full text Add to dashboard Cite

show abstract

“…In the near future, the management of a cancer patient will be driven by an integral of individual tumor biology, tumor microenvironment, host characteristics, and psychooncologic, cognitive and social entities to identify that patient -those group of patients -who will show a favorable therapeutic response [1] . However, supportive cancer care must become in parallel a mandatory service for patients to improve quality of life when undergoing treatment and entering follow-up phases.…”

mentioning

confidence: 99%

Cancer-Related Fatigue Casts a Dark Shadow Over the Quality of Life of Cancer Patients

Zaenker

2014

Inflamm Cell Signal

View full text Add to dashboard Cite

Dynamic changes of cancer-related fatigue (CRF) among colorectal cancer patients treated by chemo-or radiochemotherapy and, in addition, by supportive care with a specific mistletoe preparation, were determined. Patients completed anamnestic interviews at the beginning of the post-surgical therapy, in the midst of the intended-to-treat therapy and at the end of the chemo-or chemo-radio therapy. The retrospective results suggested that inflammatory processes are involved in CRF. Comorbidities were associated with the prevalence and severity of CRF. The supportive care delivered by mistletoe application during the postsurgical treatment period was able to decrease CRF symptoms and to improve quality of life.

show abstract

“…The authors of the present meeting report chaired the symposium. The theme was "Personalized Cancer Care," and it was a follow-up of a previous meeting held in September 2012 in Oslo [1] . Most of the speakers showed up again in 2016 and offered an update on the progress and newly arising views in their field of expertise.…”

Section: Introductionmentioning

confidence: 99%

Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy

Zänker

Børresen‐Dale

2016

Biomed Hub

Self Cite

View full text Add to dashboard Cite

At the annual prestigious International Symposium of the Fritz-Bender Foundation, Munich, 18-20 May, 2016, researchers, clinicians, and students discussed the state of the art and future perspectives of genomic medicine in cancer. Genomic medicine (also known as precision medicine/oncology) should help clinicians to provide a more precise diagnosis and therapy in oncology for individual patients. The meeting focused on next-generation sequencing methods, analytical computational analysis of big data, and data mining on the way to translational and evidence-based medicine. The meeting covered the social and ethical impact of genomic medicine as well as news and views on antibody targeting of intracellular proteins, on the architecture of intracellular proteins and their impact on carcinogenesis, and on the adaptation of tumor therapy in due consideration of tumor evolution. Subheadings like "Genetic Profiling of Patients and Risk Prediction," "Molecular Profiling of Tumors and Metastases," "Tumor-Host Microenvironment Interaction and Metabolism," and "Targeted Therapy" were subsumed under the main heading of "Personalized Cancer Care." What Is It about?This meeting report is a follow-up progress report from a previous one in 2013. It summarizes at the cutting edge how cancer manifests in the human body. Basic scientists and clinicians shared their views on personal cancer care and precision cancer medicine with special reference to epigenetic, genetic, and novel therapy strategies.

show abstract

Personalized Cancer Care Conference

Cited by 4 publications

References 19 publications

Targeting Inflammation in Cancer-Related-Fatigue: A Rationale for Mistletoe Therapy as Supportive Care in Colorectal Cancer Patients

Targeting Inflammation in Cancer-Related-Fatigue: A Rationale for Mistletoe Therapy as Supportive Care in Colorectal Cancer Patients

Cancer-Related Fatigue Casts a Dark Shadow Over the Quality of Life of Cancer Patients

Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy

Contact Info

Product

Resources

About